Acquisition of Ogeda to establish a platform for the clinical development and commercialization of fezolinetant

A specific transaction in which Ogeda SA was acquired, bringing in a clinical development pipeline including fezolinetant, which was later commercialized in the United States as VEOZAH. The transaction involved upfront consideration and additional consideration linked to development progress.